Successfully scaling up monoclonal antibody (mAb) production can be a challenge for early-stage organizations as this phase of the bioprocessing journey can pose many challenges. Developers need to be confident that their process works at larger scales while being economically feasible for long-term production. That’s why our Gibco media and feeds are designed with scalability in mind; we offer a range of robust, commercially available, and scalable protein production solutions to help streamline scale-up.
A collaboration for success
To demonstrate the scalability of our Gibco media and feed solutions, we collaborated with the Centre for Biochemical Engineering and Cell Cultivation Techniques at the Zurich University of Applied Sciences (ZHAW).
ZHAW is a leading Swiss research institution with longstanding expertise in life science and pharmaceutical innovation. Its Centre for Biochemical Engineering and Cell Cultivation Techniques has a strong reputation for research excellence in cell culture process development, with more than 20 years of bioprocessing experience. This subject matter expertise made ZHAW an ideal collaborator for this project.
Addressing speed to market & scale-up challenges
Early-stage companies often have difficulty with rapidly identifying an optimal medium and feed that maximize productivity and enable seamless scaling. Speed to market is also crucial, especially for perfusion processes where identifying the best media quickly can significantly impact production timelines. This collaboration with ZHAW aimed to tackle these challenges by evaluating the performance of two specialized mAb production solutions:
- The Gibco Efficient-Pro Medium and Feeds System: A next-generation solution consisting of an innovative medium and two premium feeds, designed to optimize fed-batch CHO-based bioproduction and support an easy transition to clinical and commercial manufacturing.
- The Gibco High-Intensity Perfusion (HIP) CHO Medium: A high-performing medium capable of supporting high cell densities at low perfusion rates, developed to enable exceptional performance in perfusion processes while offering substantial ease-of-use and scalability benefits.
Maximizing mAb upstream process efficiency
The results of this study demonstrated that both the Efficient-Pro system and HIP CHO Medium can support consistent, high-quality mAb production at a range of scales, for fed-batch and perfusion-based processes respectively. This allows developers to confidently scale up their processes while maintaining productivity and cost-efficiency, and support faster speed-to-market by quickly identifying optimal media solutions.
To find out more about this collaboration and see the data for yourself, visit our dedicated ZHAW webpage.
Take your mAb process to the next level
To learn more about these products visit our Gibco Efficient-Pro System and Gibco HIP-CHO Medium webpages, or get in touch with a bioprocessing representative to discover how these solutions can benefit your process.
Leave a Reply